Dabur India has come under scrutiny after the United States Food and Drug Administration (US FDA) reportedly identified several deficiencies at one of the company's manufacturing facilities located at Silvassa in Dadra and Nagar Haveli. The observations relate to maintenance practices, data integrity concerns and manufacturing processes, raising questions about compliance standards at the plant. The findings stem from an inspection conducted by the US regulator in January 2026. The facility is significant for the company as it manufactures products that are supplied to the American market, where Dabur has a strong presence in the Ayurvedic and healthcare segments.
Source link
Headlines
